Physician profile
Charles Edward Wingate
NPI 1619972015
$1,696.69
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $354 · 2021: $460 · 2022: $186.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $376.60 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $219.69 | 2019-2021 | |
| Ivantis, INC | $171.73 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $121.16 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $110.93 | 2022 | |
| Alcon Vision LLC | $105.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $102.46 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $82.30 | 2019-2022 | |
| Allergan, INC. | $73.98 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $72.14 | 2019-2020 | |
| Optovue, INC. | $63.42 | 2019 | |
| Sight Sciences, INC. | $40.27 | 2019-2020 | |
| Oyster Point Pharma, INC. | $39.84 | 2022 | |
| Omeros Corporation | $37.56 | 2019-2021 | |
| Biotissue Holdings INC. | $24.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $23.70 | 2019 | |
| Eyepoint US, INC. | $18.79 | 2019 | |
| Dompe US, INC. | $12.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wingate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.